Market Place
Sourcing Support
CRISPR Therapeutics Announces COO Transition
26 Mar 2025 //
GLOBENEWSWIRE
CRISPR Therapeutics Announces the Appointment of Alex Harding as Head of BD
19 Dec 2022 //
GLOBENEWSWIRE
Sickle cell cure will be cost-effective if health disparities considered
15 Dec 2022 //
REUTERS
CRISPR Therapeutics Provides Update on Its Ongoing Ph1 CARBON™ Trial of CTX110®
12 Dec 2022 //
GLOBENEWSWIRE
Vertex and CRISPR Therapeutics to Present at the ASH Annual Meeting
10 Dec 2022 //
BUSINESSWIRE
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
01 Dec 2022 //
GLOBENEWSWIRE
New CRISPR-based tool inserts large DNA sequences at desired sites in cells
28 Nov 2022 //
SCIENCEBOARD
Crispr Therapeutics: The Pick Of The Gene Therapy Bunch
18 Nov 2022 //
SEEKING ALPHA
Intellia says CRISPR candidate may offer `functional cure` for HAE
15 Nov 2022 //
PRESS RELEASE
CRISPR Therapeutics Presents Data at SITC Annual Meeting
10 Nov 2022 //
PRESS RELEASE
CRISPR Therapeutics Announces Poster Presentation on CTX110®
03 Nov 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Provides Business Update and Reports 3Q 2022 FYR
01 Nov 2022 //
GLOBENEWSWIRE
CRISPR QC Appoints Dr. Toby Richardson to CRISPR QC Board of Directors
31 Oct 2022 //
BUSINESSWIRE
Two Aurinia execs are out — and CRISPR’s operations chief isn`t far behind
28 Oct 2022 //
ENDPTS
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
27 Oct 2022 //
GLOBENEWSWIRE
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
27 Oct 2022 //
FOOL
First Week of December 16th Options Trading For CRISPR Therapeutics AG (CRSP)
21 Oct 2022 //
NASDAQ
CRISPR Therapeutics to Present at the (SITC) 37th Annual Meeting
05 Oct 2022 //
GLOBENEWSWIRE
CRISPR to Present at the BMO Biopharma Spotlight Series: Gene Editing
29 Sep 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Announces FDA RMAT Designation Granted to CTX130
29 Sep 2022 //
BIOSPACE
Vertex & CRISPR Announce Submissions for Sickle Cell Disease & Beta Thalassemia
28 Sep 2022 //
PRESS RELEASE
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions
27 Sep 2022 //
BUSINESSWIRE
Vertex and CRISPR send in their pitch for blood disorder cell therapy
27 Sep 2022 //
ENDPTS
After early wins, CRISPR gene editing is about to get a lot harder
21 Sep 2022 //
STATNEWS
2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years
19 Sep 2022 //
FOOL
CRISPR infusion eliminates swelling in those with rare genetic disease
18 Sep 2022 //
SCIENCE
Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success
16 Sep 2022 //
BARRONS
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
31 Aug 2022 //
GLOBENEWSWIRE
CRISPR QC Accepted into EvoNexus – San Diego’s Premier Startup Incubator
16 Aug 2022 //
BUSINESSWIRE
Graphite Bio begins SCD cell therapy trial
11 Aug 2022 //
ENDPOINTS NEWS
CRISPR Tx Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
CRISPR Tx`s pipeline update fails to impress investors
22 Jun 2022 //
FIERCEBIOTECH
This CRISPR Stock Plunged On Cell Therapy`s Looming Question
13 Jun 2022 //
THESTREET
CRISPR Tx Presents Positive Results from its Phase 1 COBALT-LYM Trial of CTX130
11 Jun 2022 //
GLOBENEWSWIRE
CRISPR Tx and Vertex take the air with interim CRISPR blood cell therapy data
11 Jun 2022 //
ENDPTS
Dr. Kiana Aran and Dr. Paul Grint appointed to CRISPR QC Board of Directors
09 Jun 2022 //
BUSINESSWIRE
CRISPR Therapeutics to Present at Goldman Sachs Global Healthcare Conference
08 Jun 2022 //
GLOBENEWSWIRE
Vertex and CRISPR Tx Announce Acceptance of Late-Breaking Abstract for CTX001
02 Jun 2022 //
BUSINESSWIRE
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
31 May 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Appoints Phuong Khanh Morrow, M.D., FACP, as CMO
16 May 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on CTX130
12 May 2022 //
CRISPRTX
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on CTX130
12 May 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
04 May 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
07 Apr 2022 //
GLOBENEWSWIRE
CRISPR Tx says Poster Presentation at the AACR
08 Mar 2022 //
GLOBENEWSWIRE
CRISPR Tx to Participate in Upcoming Investor Conferences
28 Feb 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics Reports Q4 and Full Year 2021 Financial Results
15 Feb 2022 //
GLOBENEWSWIRE
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Conference
09 Feb 2022 //
GLOBENEWSWIRE
CRISPR Announces FDA Regenerative Medicine Advanced Therapy (RMAT)
22 Nov 2021 //
GLOBENEWSWIRE
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy
17 Nov 2021 //
ENDPTS
CRISPR Therapeutics and ViaCyte to Start Trial of the First Gene-Edited Cell
16 Nov 2021 //
GLOBENEWSWIRE
CRISPR Therapeutics Provides Business Update and Reports Q3 2021 Results
03 Nov 2021 //
BIOSPACE
CRISPR co-founder uncloaks an off-the-shelf cell therapy startup with $86M
03 Nov 2021 //
ENDPTS
Underpinning Sinema’s outspoken opposition to major drug pricing reforms
19 Oct 2021 //
STATNEWS
CRISPR touts new results as fresh questions surround `off-the-shelf` CAR-T
13 Oct 2021 //
BIOPHARMADIVE
Crispr’s reminder about allogeneic Car-T redosing
13 Oct 2021 //
EVALUATE
UPDATE: CRISPR hails safety, efficacy of off-the-shelf CAR-Ts
13 Oct 2021 //
FIERCEBIOTECH
CRISPR claims safety advantage in off-the-shelf CAR-T data; questions durability
13 Oct 2021 //
ENDPTS
CRISPR Therapeutics shares fall after updated results from CTX110 cancer study
12 Oct 2021 //
SEEKINGALPHA
